Eli Lilly has to wait a while longer for FDA verdict

Partners Eli Lilly and Incyte will have to wait until Q3 to find out whether the US health authorities can approve their drug Oluminant as a treatment for atopic dermatitis.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly's application to get approval for the drug Olumiant, which treats atopic dermatitis in adults, according to an Eli Lilly press announcement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading